Efficacy News and Research

RSS
Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

POLAR gene profile predicts which patients may and may not benefit from radiation therapy after breast-conserving surgery

Complementary, alternative therapies for heart failure have some benefits and potential risks

Complementary, alternative therapies for heart failure have some benefits and potential risks

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

Trial establishes the clinical utility of circulating tumor cell count as biomarker in breast cancer care

COVID-19 vaccines may reduce long-COVID symptoms

COVID-19 vaccines may reduce long-COVID symptoms

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Scientists report the in vitro production of infectious Plasmodium falciparum sporozoites

Scientists report the in vitro production of infectious Plasmodium falciparum sporozoites

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Exploring immunogenicity, boosting efficacy and safety of modified vaccinia Ankara-Bavarian Nordic vaccine

Innovative precision oncology enabled by micro-organospheres derived from patients

Innovative precision oncology enabled by micro-organospheres derived from patients

COVID-19 vaccination may cause temporary menstrual disturbances in adolescent girls

COVID-19 vaccination may cause temporary menstrual disturbances in adolescent girls

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

Higher dose of new antimalarial drug reduces disease recurrence by 85%

Higher dose of new antimalarial drug reduces disease recurrence by 85%

The critical role of flow cytometry in CAR+ T-Cell trials

The critical role of flow cytometry in CAR+ T-Cell trials

Is remdesivir treatment associated with reduced risk of inpatient mortality among US patients hospitalized with COVID-19?

Is remdesivir treatment associated with reduced risk of inpatient mortality among US patients hospitalized with COVID-19?

MHRA authorizes the use of Pfizer/Biontech COVID-19 vaccine in kids aged 6 months to 4 years

MHRA authorizes the use of Pfizer/Biontech COVID-19 vaccine in kids aged 6 months to 4 years

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.